Abstract
Drug allergies are heterogeneous and multifactorial diseases and are always the consequence of an exaggerated immune-mediated reaction. Previously described models of immunologic mechanisms (mainly based on Gell and Combs classification) cannot fully explain the physiopathology of these diseases; it seems therefore important to identify risk factors. Clinical and biologic tests are helpful diagnostic tools but are limited in their sensitivity and reliability and are certainly not predictive. Epidemiologic data supply information concerning the prevalence of drug hypersensitivity: female gender, concomitant infections (HIV, herpes) and concurrent illnesses (systemic lupus erythematosus) are all significant risk factors. Another host-related factor is the genetic predisposition of patients and is currently under investigation in our laboratory. Most genetic studies concern HLA haplotype association or polymorphism in genes encoding drugmetabolising enzymes. A current study by our group seems to implicate polymorphisms within the promoter of IL-10, a cytokine with anti-inflammatory properties. The chemical properties of the drug and the treatment regimen also influence the development of drug allergies.
Keywords: Drug allergies, risk factors, β-lactam allergy, SNP
Current Pharmaceutical Design
Title: Drug Hypersensitivity: Epidemiology and Risk Factors
Volume: 12 Issue: 26
Author(s): L. Guglielmi, P. Guglielmi and P. Demoly
Affiliation:
Keywords: Drug allergies, risk factors, β-lactam allergy, SNP
Abstract: Drug allergies are heterogeneous and multifactorial diseases and are always the consequence of an exaggerated immune-mediated reaction. Previously described models of immunologic mechanisms (mainly based on Gell and Combs classification) cannot fully explain the physiopathology of these diseases; it seems therefore important to identify risk factors. Clinical and biologic tests are helpful diagnostic tools but are limited in their sensitivity and reliability and are certainly not predictive. Epidemiologic data supply information concerning the prevalence of drug hypersensitivity: female gender, concomitant infections (HIV, herpes) and concurrent illnesses (systemic lupus erythematosus) are all significant risk factors. Another host-related factor is the genetic predisposition of patients and is currently under investigation in our laboratory. Most genetic studies concern HLA haplotype association or polymorphism in genes encoding drugmetabolising enzymes. A current study by our group seems to implicate polymorphisms within the promoter of IL-10, a cytokine with anti-inflammatory properties. The chemical properties of the drug and the treatment regimen also influence the development of drug allergies.
Export Options
About this article
Cite this article as:
Guglielmi L., Guglielmi P. and Demoly P., Drug Hypersensitivity: Epidemiology and Risk Factors, Current Pharmaceutical Design 2006; 12 (26) . https://dx.doi.org/10.2174/138161206778194088
DOI https://dx.doi.org/10.2174/138161206778194088 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antivenoms for Snakebite Envenomings
Inflammation & Allergy - Drug Targets (Discontinued) Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety Fixed Drug Eruption Due to Selective Hypersensitivity to Naproxen with Tolerance to other Propionic Acid NSAIDs
Recent Patents on Inflammation & Allergy Drug Discovery Pharmacogenetic Determinants of Immediate and Delayed Reactions of Drug Hypersensitivity
Current Pharmaceutical Design A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Challenges in the Management of Severe Asthma: Role of Current and Future Therapies
Current Pharmaceutical Design Editorial [Hot topic: Recent Progress in Cancer Therapeutics (Guest Editor: Kurt S. Zaenker)]
Current Molecular Medicine Editorial (Mini-Thematic Issue: Mold Allergens and Antigenic Epitopes Correlation with Fungal Diseases)
Current Protein & Peptide Science Filariasis: Current Status, Treatment and Recent Advances in Drug Development
Current Medicinal Chemistry Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Hypersensitivity Reactions from Excipients in Systemic Glucocorticoid Formulations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?
Current Cardiology Reviews Hypersensitivity to Hymenoptera Venom: Advances in Diagnosis and Implications for Treatment
Recent Patents on Inflammation & Allergy Drug Discovery A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia
Current Drug Safety Editorial [Hot Topic: Antihistamines (Guest Editor: Esen Ozkaya)]
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Drugs in Pediatric Ischemic Stroke
Current Drug Targets Angiotensin Converting Enzyme (ACE) Inhibitory Peptides: Production and Implementation of Functional Food
Current Pharmaceutical Design Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets Hypertensive Pharmacogenomics in African Americans
Current Pharmacogenomics